trial
as of 2026-07-01Sodium Butyrate For Improving Cognitive Function In Schizophrenia
NCTId NCT03010865
at a glance
Phase 2, Phase 3 · Withdrawn
Enrollment 0 (actual)
Sponsored by Shanghai Mental Health Center
Primary completion 2019-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-06-01
Primary completion
2019-12
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
Shanghai Mental Health CenterLead Sponsor
Stanley Medical Research InstituteCollaborator
Investigators
1
Chunbo Li, Ph.D.Principal Investigator
Sites
1 total
Shanghai, China
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
0
Phase
PHASE2,PHASE3
Primary Completion Date
2019-12
Status
WITHDRAWN
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person